S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
Log in

Palatin Technologies Stock Price, Forecast & Analysis (NYSEAMERICAN:PTN)

$0.82
+0.03 (+3.82 %)
(As of 11/11/2019 04:00 PM ET)
Today's Range
$0.78
Now: $0.82
$0.82
50-Day Range
$0.87
MA: $0.93
$1.06
52-Week Range
$0.59
Now: $0.82
$1.78
Volume976,559 shs
Average Volume1.88 million shs
Market Capitalization$185.04 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PTN
CUSIPN/A
Phone+1-609-4952200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees19
Market Cap$185.04 million
Next Earnings Date11/13/2019 (Confirmed)
OptionableNot Optionable

Receive PTN News and Ratings via Email

Sign-up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter.


Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions

What is Palatin Technologies' stock symbol?

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) announced its quarterly earnings results on Thursday, September, 12th. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.03) by $0.26. The biopharmaceutical company had revenue of $60.27 million for the quarter. View Palatin Technologies' Earnings History.

When is Palatin Technologies' next earnings date?

Palatin Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Palatin Technologies.

How can I listen to Palatin Technologies' earnings call?

Palatin Technologies will be holding an earnings conference call on Wednesday, November 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for PTN?

3 brokers have issued 12 month target prices for Palatin Technologies' shares. Their forecasts range from $3.00 to $8.00. On average, they anticipate Palatin Technologies' share price to reach $5.67 in the next year. This suggests a possible upside of 595.3% from the stock's current price. View Analyst Price Targets for Palatin Technologies.

What is the consensus analysts' recommendation for Palatin Technologies?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Palatin Technologies.

What are Wall Street analysts saying about Palatin Technologies stock?

Here are some recent quotes from research analysts about Palatin Technologies stock:
  • 1. According to Zacks Investment Research, "Palatin Technologies, Inc is a development-stage medical technology company involved in developing and commercializing products and technologies for diagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling peptide platform technologies. " (8/27/2019)
  • 2. HC Wainwright analysts commented, "Our thesis on shares remains unchanged; major boxes checked and valuation disconnect exists, in our belief. Significant boxes have already been checked off, which we believe provide a derisked opportunity for investors." (1/11/2019)

Has Palatin Technologies been receiving favorable news coverage?

News articles about PTN stock have trended very negative this week, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Palatin Technologies earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Palatin Technologies.

Are investors shorting Palatin Technologies?

Palatin Technologies saw a decrease in short interest in October. As of October 15th, there was short interest totalling 22,600,000 shares, a decrease of 9.0% from the September 15th total of 24,840,000 shares. Based on an average daily volume of 1,200,000 shares, the days-to-cover ratio is currently 18.8 days. Approximately 10.6% of the company's stock are short sold. View Palatin Technologies' Current Options Chain.

Who are some of Palatin Technologies' key competitors?

What other stocks do shareholders of Palatin Technologies own?

Who are Palatin Technologies' key executives?

Palatin Technologies' management team includes the folowing people:
  • Dr. John K. A. Prendergast, Co-Founder & Non-Exec. Chairman (Age 65)
  • Dr. Carl Spana, Co-Founder, Pres, CEO & Director (Age 57)
  • Mr. Stephen T. Wills CPA, CPA, MST, CFO, COO, Exec. VP, Treasurer & Sec. (Age 62)
  • Burns McClellan, VP of Investor Relations

Who are Palatin Technologies' major shareholders?

Palatin Technologies' stock is owned by a number of of retail and institutional investors. Top institutional investors include California Public Employees Retirement System (0.26%), First Trust Advisors LP (0.20%), Commonwealth Equity Services LLC (0.03%), Meeder Asset Management Inc. (0.03%) and Summit X LLC (0.01%). Company insiders that own Palatin Technologies stock include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View Institutional Ownership Trends for Palatin Technologies.

Which institutional investors are buying Palatin Technologies stock?

PTN stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Meeder Asset Management Inc., Commonwealth Equity Services LLC, California Public Employees Retirement System and Summit X LLC. Company insiders that have bought Palatin Technologies stock in the last two years include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View Insider Buying and Selling for Palatin Technologies.

How do I buy shares of Palatin Technologies?

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Palatin Technologies' stock price today?

One share of PTN stock can currently be purchased for approximately $0.82.

How big of a company is Palatin Technologies?

Palatin Technologies has a market capitalization of $185.04 million. Palatin Technologies employs 19 workers across the globe.View Additional Information About Palatin Technologies.

What is Palatin Technologies' official website?

The official website for Palatin Technologies is http://www.palatin.com/.

How can I contact Palatin Technologies?

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.


MarketBeat Community Rating for Palatin Technologies (NYSEAMERICAN PTN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  356 (Vote Outperform)
Underperform Votes:  261 (Vote Underperform)
Total Votes:  617
MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote "Outperform" if you believe PTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/11/2019 by MarketBeat.com Staff

Featured Article: Operating Income

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel